Sirion Holdings

Sirion Biotech is a leading provider of viral vector technologies and services, specializing in the design and manufacture of AAV, lentivirus, and adenovirus vectors for gene therapy and vaccine development. The company's proprietary LentiBOOST platform is a widely recognized technology for enhancing lentiviral transduction efficiency in clinical applications, particularly in CAR-T and stem cell therapies. Sirion Biotech offers end-to-end support from vector engineering and optimization to clinical-scale production, catering to a global client base of pharmaceutical and biotechnology companies. In 2021, the company was acquired by PerkinElmer (now Revvity) to strengthen its cell and gene therapy portfolio. Their expertise in viral vector evolution and custom vector design makes them a critical partner in the development of next-generation genetic medicines.